Is whole-body FDG-PET valuable for health screening? Against.
Weckesser
Matthias
M
Department of Nuclear Medicine, Münster University, Albert-Schweitzer-Strasse 33, 48149, Münster, Germany. m.weckesser@uni-muenster.de
Schober
Otmar
O
D019788:Fluorodeoxyglucose F18; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D009369:Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods* / Q000706:statistics & numerical data; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D019275:Radiopharmaceuticals; D014915:Whole-Body Counting / Q000379:methods*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
Radiology. 2004 Feb;230(2):417-22
14699176
Ann Oncol. 2004;15 Suppl 1:I18-I26
15280183
N Engl J Med. 2000 Nov 30;343 (22):1627-33
11096172
Circulation. 2002 Jan 22;105(3):310-5
11804985
Neoplasma. 2003;50(3):217-21
12937856
Eur J Nucl Med. 1998 Jun;25(6):565-74
9618570
Anticancer Res. 2003 Sep-Oct;23 (5b):4357-61
14666651
Eur J Nucl Med. 2001 Dec;28(12 ):1766-9
11734913
Lancet. 2003 Aug 23;362(9384):593-7
12944057
Br J Cancer. 2000 Dec;83(12 ):1607-11
11104553
J Nucl Med. 2001 Jul;42(7):989-92
11438616